Biovica will present at Stora Aktiedagen, a small-cap investor conference, held on November 12 at Svenska Mässan in Gothenburg. The event is arranged by Aktiespararna and the company will be represented by CEO Anders Rylander in hall 2 at 9.20 CET.
For full program and registration, see link: www.aktiespararna.se/aktiviteter/stora-aktiedagen-goteborg-2018
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.
Read more: www.biovica.com